



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

N-Deshydroxyethyl Dasatinib

Cat. No.:	HY-107447
CAS No.:	910297-51-7
Molecular Formula:	C ₂₀ H ₂₂ ClN ₇ OS
Molecular Weight:	443.95
Target:	Drug Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 55 mg/mL (123.89 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.2525 mL	11.2625 mL	22.5251 mL
		5 mM		0.4505 mL	2.2525 mL	4.5050 mL
		10 mM		0.2253 mL	1.1263 mL	2.2525 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.75 mg/mL (6.19 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.75 mg/mL (6.19 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.75 mg/mL (6.19 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research ^{[1][2]} .
In Vivo	Pharmacokinetic Parameters of N-Deshydroxyethyl Dasatinib in Wistar Rats ^[2] .

Analyte	C _{max} (ng/mL)	AUC _{0-t} (h*ng/mL)	AUC _{0-inf} (h*ng/mL)	T _{max} (h)	T _{1/2} (h)	K _{el} (h ⁻¹)
N- Deshydroxyethyl Dasatinib	2.05	8.7	23.9	2.0	10.293	0.072

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Thappali SR, et al. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. *Arzneimittelforschung*. 2012 Dec;62(12):624-30.
- [2]. Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. *Cancer Sci*. 2017 Aug;108(8):1657-1666.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA